A Possible contributor to Erythropoiesis-Stimulating Agents Requirement in Hemodialysis: Paraoxonase 1 Activity

Berfu KORUCU1, Hasan YETER1, Elif Burcu BALI2, Mehmet Kursat DERICI3, Galip GUZ1

1Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey
2Gazi University Vocational School of Health Services, Ankara, Turkey
3Department of Pharmacology, Kirikkale University Faculty of Medicine, Kirikkale, Turkey

ABSTRACT

Background: Anemia is one of the most prevalent complications of chronic kidney disease. In chronic kidney disease-related anemia, circulating erythrocytes have a decreased life span. Paraoxonase-1 activity is one of the essential factors protecting cell membranes, e.g., erythrocytes, from lipid peroxidation under normal conditions. In this study, we investigated Paraoxonase-1 activity in hemodialysis patients with and without erythropoiesis-stimulating agent therapy and the possible relationship of Paraoxonase-1 activity levels with the erythropoiesis-stimulating agent dose required.

Material and Methods: This study is composed of patients undergoing hemodialysis with a minimum dialysis vintage of six months. We excluded cases with an active infection, cardiovascular events and malignancy, hypo- or hyperthyroidism, central venous catheters, iron deficiency, cystic kidney diseases, nephrectomy, and routine C-reactive protein levels higher than reference range within the last six months.

Results: Baseline characteristics, laboratory parameters, oxidative stress, and systemic inflammatory indices were similar between groups. The mean Paraoxonase-1 activity of the erythropoiesis-stimulating agent+group was significantly lower than the erythropoiesis-stimulating agent–group (191.4±118.8 and 488.1±174.9, respectively; p<0.001). Cumulative erythropoiesis-stimulating agent doses and Paraoxonase-1 activity were significantly and negatively correlated (R=-0.736, p<0.001).

Conclusions: The results of this study suggest that lower Paraoxonase-1 activity in hemodialysis patients is associated with the requirement for erythropoiesis-stimulating agent therapy, presumably due to decreased life span of erythrocytes. Further studies examining the relationship between Paraoxonase-1 activity and erythropoiesis-stimulating agent treatment requirements are necessary to reveal new treatment goals for chronic kidney disease-related anemia.

Keywords: Hepatitis B, Rheumatoid arthritis, Parenteral therapies.
Introduction

Anemia is one of the most prevalent complications of chronic kidney disease (CKD). In CKD related anemia, circulating erythrocytes have a decreased life span, and compensatory erythropoiesis is decreased. In the latter, the most prominent mechanism is the reduction in intrinsic erythropoietin (EPO) secretion. However, the secretion of EPO remains significant even in end-stage renal disease in patients without total nephrectomy. The primary condition that requires the use of erythropoiesis-stimulating agents (ESA) is patients’ blunt response to low hemoglobin (Hb) level. On the other hand, every patient’s need for ESA treatment is not the same, and even some patients persistently have adequate Hb levels without ESA.

The pathophysiological mechanism of decreased erythrocyte life span in CKD patients has not been clarified. Studies investigating the possible mechanical effects of hemodialysis have failed to reveal significant differences with peritoneal dialysis patients. The so-called “uremic milieu” in CKD describes numerous pathophysiological mechanisms such as increased uremic toxins, systemic inflammation, and oxidative stress. On the other hand, there is an inadequacy in the mechanisms that balance these phenomena.

Among the components of the “uremic milieu,” one of the significant pathophysiological mechanisms that concern cellular life span is the increased cell membrane lipid peroxidation in chronic renal failure. Paraoxonase-1 (PON1) activity in high-density lipoprotein (HDL) is one of the essential factors protecting cell membranes, e.g., erythrocytes, from lipid peroxidation under normal conditions. The protective effect of PON1 on the erythrocyte membrane is observed in animal models and human studies.

Studies have shown that patients with CKD have decreased PON1 activity compared to the healthy population, and revealed its adverse outcomes on patient survival. In this study, we investigated PON1 activity in HD patients with and without ESA therapy, excluding cases with total nephrectomy or cystic kidney diseases, anemia not related to CKD, and factors that may cause ESA resistance. We also analyzed the possible relationship of PON1 activity levels with the ESA dose required.

Material and Methods

Statement of Ethics

The study protocol was approved by an independent research institute’s committee on human research.

Study Design, Participants, and Definitions

This cross-sectional study is composed of 50 patients undergoing HD with a minimum dialysis vintage of six months. We excluded cases with an active infection, an active or recent history of any cardiovascular events and malignancy, hypo- or hyperthyroidism, central venous catheters, iron deficiency, prosthetic heart valves, unilateral or bilateral nephrectomy, polycystic kidney disease or acquired kidney cysts, routine C-reactive protein (CRP) levels higher than reference range within the last six months, a calculated erythropoietin resistance index (ERI) of ≥5 U/kg/week/g/dL, and a single pool Kt/V of ≤1.2. Informed consent was obtained from all patients for being included in the study.

The ERI was calculated as the weekly recombinant human erythropoietin (rhEPO) dose divided by the body weight and the hemoglobin concentration. Mean weekly and cumulative rhEPO doses applied within the last six months were calculated. Doses of darbepoetin were converted to equivalent doses of epoetin for standardization. Patients with >100 mL/day urine output were considered to have a residual renal function (RRF). Single pool Kt/V calculated by Daugirdas’ second-generation formula. Urea reduction ratio (URR) calculated by taking the difference between pre- and post-dialysis urea levels and divided by predialysis urea levels.

All of the patients treated with a standard HD procedure via A-V fistulae, each session lasted 4 hours, three times a week, using bicarbonate-containing dialysate and low-flux polysulfone membrane. The blood flow rate ranged from 300 to 350 mL/min, and the dialysate flow rate was 500 mL/min.
Blood Specimen Collection

Blood specimens were collected at the initiation of a mid-week session. Specimens were allowed to clot at room temperature for 30 minutes. Clot removed by centrifuging samples at 3500 rpm for 10 minutes. The serum immediately transferred into a polypropylene tube and stored at -80°C.

Materials and Measurements

Total oxidant status (TOS) and total antioxidant status (TAS), high sensitive CRP (hsCRP), interleukin-6 (IL-6), and PON1 activity were measured from freshly collected serum. Last (within two weeks) blood urea nitrogen (BUN), creatinine (cre), albumin (alb), hemogram test, and lipid profile results were evaluated retrospectively. The mean value of the last six months was calculated for intact parathormone and ferritin levels. Patients’ demographic features such as age, sex, and body mass index were noted.

Biochemical Study

Serum levels of hsCRP were studied by the nephelometric technique using BN II/BN ProSpec (Siemens, Marburg, Germany), and IL-6 were studied by chemiluminescence immunoassay technique using Immulite 2000 (Siemens Diagnostics, Gwynedd, UK).

Total oxidant status (TOS) and total antioxidant status (TAS) levels were measured using commercially available kits (RelAssay Diagnostics, Ankara, Turkey). The ratio of TOS to TAS accepted as the OS index (OSI). For calculation, the unit of TAS converted to μmol/L, and the OSI calculated according to the following formula: OSI (arbitrary unit) = TOS (μmol H2O2 equivalent/L)/TAS (μmol Trolox equivalent/L). PON1 activity was measured using commercially available kits (RelAssay, Ankara, Turkey). The rate of paraoxon hydrolysis (diethylpnitrophenylphosphate) was measured by monitoring the increase of absorption at 412 nm at 37 °C. The amount of generated p-nitrophenol was calculated from the molar absorption coefficient at pH 8.5, which was 18.290 M⁻¹ cm⁻¹. PON1 activity was expressed as U/L.

Statistical Methods

Patients were grouped as “ESA+” and “ESA–” according to rhEPO or darbepoetin requirements within the last six months. Numeric values of the study were shown with mean and standard deviation or medians with ranges, categorical data, frequency, and percentage. For data normally disturbed, Unpaired Student’s T-Test is used for comparison between two groups. For abnormal distributed data Kruskal-Wallis test performed. Pearson correlation test was used to find a correlation between continuous variables. A p-value of less than 0.05 was considered statistically significant. All statistical analyses were performed using the Statistical Package for Social Science (SPSS, Chicago, IL, USA) for personal computers, version 21.0.

Results

Baseline Characteristics

The demographic characteristics, laboratory parameters including hemoglobin, ferritin and HDL, six months cumulative iron doses, dialysis adequacy calculations, HD vintages, and RRFs of patients in the ESA+ and ESA- groups were similar (Table 1).

Systemic Inflammation and Oxidative Stress Indices of the Groups

The mean hsCRP and IL-6 levels of patients in the ESA+ and ESA- groups were similar. Similarly, the TOS, TAS, and calculated OSIs of the groups were similar. The mean PON1 activity of the ESA+ group was significantly lower than the ESA– group (191.4±118.8 and 488.1±174.9, respectively; p<0.001) (Table 2).

Correlations of PON1 Activity with Patient-Related Factors, Oxidative Stress, and Cumulative ESA Doses

There was no significant correlation between age, BMI, dialysis time, HDL level or OSI, and PON1 activity, as shown in Table 3 and Figure 1. Cumulative ESA doses and PON1 activity were significantly and negatively correlated (R=-0.736, p<0.001).

Discussion

The results of our study suggest that the serum PON1 activity is significantly lower in HD patients requiring ESA therapy, and PON1 activity significantly correlates with cumulative
Table 1. Baseline characteristics and laboratory parameters of the groups

<table>
<thead>
<tr>
<th></th>
<th>ESA+ (n=32)</th>
<th>ESA- (n=18)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/male (n)</td>
<td>14/18</td>
<td>5/13</td>
<td>0.273</td>
</tr>
<tr>
<td>Age mean (SD)</td>
<td>58.6 (±14.7)</td>
<td>55.1 (±16.3)</td>
<td>0.437</td>
</tr>
<tr>
<td>BMI, kg/m² (SD)</td>
<td>23.4 (±4.9)</td>
<td>25.6 (±5.1)</td>
<td>0.150</td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td>6 (18.8%)</td>
<td>4 (22.2%)</td>
<td>0.774</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>7 (21.8%)</td>
<td>5 (27.7%)</td>
<td>0.647</td>
</tr>
<tr>
<td>BUN mean, mg/dL (SD)</td>
<td>67.1 (±16.2)</td>
<td>57.6 (±15.7)</td>
<td>0.067</td>
</tr>
<tr>
<td>Creatinine mean, mg/dL (SD)</td>
<td>8.4 (±1.7)</td>
<td>8.1 (±2.0)</td>
<td>0.543</td>
</tr>
<tr>
<td>Hemoglobin mean, g/dL (SD)</td>
<td>11.3 (±1.2)</td>
<td>11.2 (±2.0)</td>
<td>0.831</td>
</tr>
<tr>
<td>Albumin mean, g/dL (SD)</td>
<td>3.8 (±0.3)</td>
<td>3.8 (±0.3)</td>
<td>0.837</td>
</tr>
<tr>
<td>iPTH median, pg/mL (min-max)</td>
<td>314.5 (14-1834)</td>
<td>296 (69.2-1401.1)</td>
<td>0.693</td>
</tr>
<tr>
<td>Ferritin mean, ng/mL (SD)</td>
<td>568.6 (±174.7)</td>
<td>499.5 (±281.0)</td>
<td>0.289</td>
</tr>
<tr>
<td>LDL mean, mg/dL (SD)</td>
<td>107.7 (±42.4)</td>
<td>101.0 (±35.1)</td>
<td>0.570</td>
</tr>
<tr>
<td>Triglyceride mean, mg/dL (SD)</td>
<td>204.0 (±140.6)</td>
<td>184.0 (±114.7)</td>
<td>0.626</td>
</tr>
<tr>
<td>HDL mean, mg/dL (SD)</td>
<td>38.6 (±8.9)</td>
<td>38.3 (±10.8)</td>
<td>0.916</td>
</tr>
<tr>
<td>IV iron median, mg (min-max)</td>
<td>600 (0-2200)</td>
<td>600 (0-1200)</td>
<td>0.074</td>
</tr>
<tr>
<td>ACEI/ARB use, n (%)</td>
<td>5 (15.6%)</td>
<td>2 (11.1%)</td>
<td>0.303</td>
</tr>
<tr>
<td>Kt/V mean (SD)</td>
<td>1.6 (±0.3)</td>
<td>1.6 (±0.4)</td>
<td>0.880</td>
</tr>
<tr>
<td>URR (%) mean (SD)</td>
<td>75.2 (±6.2)</td>
<td>74.6 (±7.0)</td>
<td>0.747</td>
</tr>
<tr>
<td>HD vintage mean, months (SD)</td>
<td>70.6 (±56.7)</td>
<td>62.8 (±48.3)</td>
<td>0.629</td>
</tr>
<tr>
<td>RRF, n (%)</td>
<td>11 (34.3%)</td>
<td>6 (33.3%)</td>
<td>0.942</td>
</tr>
</tbody>
</table>


Table 2. Systemic inflammation and oxidative stress indices of the groups

<table>
<thead>
<tr>
<th></th>
<th>ESA+ (n=32)</th>
<th>ESA- (n=18)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsCRP mean, mg/L (SD)</td>
<td>5.20 (±2.4)</td>
<td>4.34 (±2.2)</td>
<td>0.223</td>
</tr>
<tr>
<td>IL-6 mean, pg/mL (SD)</td>
<td>3.8 (±0.9)</td>
<td>3.7 (±0.9)</td>
<td>0.791</td>
</tr>
<tr>
<td>TOS mean, μmol/L (SD)</td>
<td>3.22 (±2.3)</td>
<td>3.14 (±2.5)</td>
<td>0.917</td>
</tr>
<tr>
<td>TAS mean, μmol/L (SD)</td>
<td>2.33 (±0.2)</td>
<td>2.31 (±0.3)</td>
<td>0.747</td>
</tr>
<tr>
<td>OSI</td>
<td>0.13 (±0.1)</td>
<td>0.14 (±0.1)</td>
<td>0.970</td>
</tr>
<tr>
<td>PON1 mean, U/L (SD)</td>
<td>191.4 (±118.8)</td>
<td>488.1 (±174.9)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

hsCRP: high sensitive C-reactive protein, IL-6-interleukin-6, TOS: total oxidant status, TAS: total antioxidant status, OSI: oxidative stress index, PON1: paraoxonase-1 activity
ESA doses. PON1 activity is not associated with age, BMI, serum HDL levels, dialysis vintage, and oxidative stress index.

Decreased erythrocyte life span is one of the major determinants of CKD related anemia. Median erythrocyte life span decreased by 20% in HD patients compared with healthy controls. However, the reason for this significant decrease is not well understood. In one study, IL-6, IL-18, IL-10, and hsCRP levels were compared with the erythrocyte life span, but no association was found. On the other hand, in this study,
erythrocyte life span and uric acid were positively correlated. This finding suggests that antioxidant mechanisms may have a role in this subject.

HDL is a lipoprotein that binds high-density cholesterol, takes part in the transport of cholesterol from the periphery to the liver, and is inversely associated with cardiovascular morbidities. HDL is composed of apolipoprotein A-I and A-II and also many antioxidant proteins, including PON1. PON1 is now considered to be more prominent than HDL as the source of positive cardiovascular effects. The human PON1 gene is on chromosome 7 and encodes PON1, PON2, and PON3. PON1 is synthesized in the liver and transported to the periphery by HDL to perform hydrolysis of oxidized phospholipids on cellular membranes. These uniform features make PON1 one of the future treatment targets.

PON1 activity was found to be lower in HD patients compared to the healthy population and associated with adverse cardiovascular outcomes. Although there is no study directly examining the relationship between PON1 activity and anemia, there is evidence suggesting that its lower activity may also be associated with CKD related anemia. Riberio et al. investigated factors associated with PON1 activity level in HD patients and found lower activity in patients with systemic inflammation, longer dialysis vintage, and higher dose ESA therapy. Another study suggested that HD patients had increased hemolysis susceptibility of erythrocytes with lower PON1 activity.

The possible cause of this significant PON1 activity difference in two similar HD groups may be due to PON1 gene polymorphisms. To date, two polymorphisms of PON1 and three polymorphisms of its promoter region was defined. However, the results of the studies are controversial in terms of the clinical significance of these polymorphisms. In addition, epigenetic factors have been reported to have an important effect on PON1 activity. Further studies are needed to clarify the effect of genetic and epigenetic factors on PON1 expression and activity in the HD population.

We designed our study to be suitable for understanding the relationship between PON1 activity and ESA treatment requirements in HD patients. To ensure this, we excluded all possible factors that contribute to the development of anemia in CKD patients. However, these strict exclusion criteria may have prevented us from observing factors that may affect PON1 activity levels. In order to confirm the results we obtained in our study, studies designed to directly examine the relationship between PON1 activity and erythrocyte life span in HD patients is needed. Thus, the pathophysiology of CKD-related anemia will be better understood, and new targets for treatment can be introduced.

Conclusions

The results of this study suggest that lower PON1 activity in HD patients may be associated with the requirement for ESA therapy. Further studies examining the relationship between PON1 activity and ESA treatment requirements are necessary to reveal new treatment goals for CKD-related anemia.

Conflict of Interest

The authors declare that they have no conflict of interest.

Acknowledgements

All expenditures of the study were sponsored by the Internal Diseases Postgraduate Education Association, Turkey.

Authors' Contribution

Study Conception: BK; Study Design: BK, HY, EBB; Supervision: GG; Fundings: GG; Materials: BK, HY; Data Collection and/or Processing: BK, HY; Statistical Analysis and/or Data Interpretation: BK, HY; Literature Review: BK, HY, EBB, MKD; Manuscript Preparation: BK, HY; Critical Review: MKD, GG; Biochemical Measurements: EBB

References


This is an open access article distributed under the terms of Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International License.